[
  {
    "ts": null,
    "headline": "Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie \"The More the Merrier\"",
    "summary": "This holiday season, global healthcare leader Abbott is adding even more heart to Hallmark Channel's beloved \"Countdown to Christmas\" lineup with a story that features a special community and is sure to spread joy and inspiration. \"The More the Merrier,\" a new original Hallmark movie, features real-life heroes from Abbott HeartMates, a program that provides support for people impacted by heart health challenges. The movie is set to premiere during Hallmark's Merry Thanksgiving Weekend during \"Co",
    "url": "https://finnhub.io/api/news?id=e1a6c1403d8d23dba4dd489800bd7917f73dcb36c236812eed4c6a261c5fece7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762264800,
      "headline": "Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie \"The More the Merrier\"",
      "id": 137312212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "This holiday season, global healthcare leader Abbott is adding even more heart to Hallmark Channel's beloved \"Countdown to Christmas\" lineup with a story that features a special community and is sure to spread joy and inspiration. \"The More the Merrier,\" a new original Hallmark movie, features real-life heroes from Abbott HeartMates, a program that provides support for people impacted by heart health challenges. The movie is set to premiere during Hallmark's Merry Thanksgiving Weekend during \"Co",
      "url": "https://finnhub.io/api/news?id=e1a6c1403d8d23dba4dd489800bd7917f73dcb36c236812eed4c6a261c5fece7"
    }
  },
  {
    "ts": null,
    "headline": "Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial",
    "summary": "Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin",
    "url": "https://finnhub.io/api/news?id=170094fff1193673995695d553504b3b18ca595dba284f35a717b5b07a359f18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762262100,
      "headline": "Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial",
      "id": 137312213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin",
      "url": "https://finnhub.io/api/news?id=170094fff1193673995695d553504b3b18ca595dba284f35a717b5b07a359f18"
    }
  },
  {
    "ts": null,
    "headline": "With 80% ownership, Abbott Laboratories (NYSE:ABT) boasts of strong institutional backing",
    "summary": "Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...",
    "url": "https://finnhub.io/api/news?id=3e2476b65f58ee699aa81e786d75a78dc952fa57e41257ac84068869674164a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762261214,
      "headline": "With 80% ownership, Abbott Laboratories (NYSE:ABT) boasts of strong institutional backing",
      "id": 137312214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...",
      "url": "https://finnhub.io/api/news?id=3e2476b65f58ee699aa81e786d75a78dc952fa57e41257ac84068869674164a2"
    }
  },
  {
    "ts": null,
    "headline": "$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions",
    "summary": "The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an",
    "url": "https://finnhub.io/api/news?id=771db1e5630e8730bfc08d36ccd650512c1dd6ea7e1e533f3452b69b0affd8a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762258140,
      "headline": "$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions",
      "id": 137312064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an",
      "url": "https://finnhub.io/api/news?id=771db1e5630e8730bfc08d36ccd650512c1dd6ea7e1e533f3452b69b0affd8a4"
    }
  },
  {
    "ts": null,
    "headline": "Q3 Earnings Outperformers: Abbott Laboratories (NYSE:ABT) And The Rest Of The Medical Devices & Supplies - Diversified Stocks",
    "summary": "Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Abbott Laboratories (NYSE:ABT) and its peers.",
    "url": "https://finnhub.io/api/news?id=3e32ee1c9a4208bffdf812298c36a4a043fcdb3be8a73b328a98a9bcb5b51862",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762227129,
      "headline": "Q3 Earnings Outperformers: Abbott Laboratories (NYSE:ABT) And The Rest Of The Medical Devices & Supplies - Diversified Stocks",
      "id": 137312216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Abbott Laboratories (NYSE:ABT) and its peers.",
      "url": "https://finnhub.io/api/news?id=3e32ee1c9a4208bffdf812298c36a4a043fcdb3be8a73b328a98a9bcb5b51862"
    }
  }
]